Introduction {#Sec1}
============

Bacterial meningitis is a severe infection of the central nervous system, which is caused by *Streptococcus pneumoniae* in 70 % of cases \[[@CR1]\]. Patients with pneumococcal meningitis are at high risk for complications, such as epileptic seizures and cerebral infarction, resulting in a high mortality rates, and neurologic sequelae, including hearing loss, focal neurological deficit, and cognitive impairment, in almost half of survivors \[[@CR2]--[@CR7]\]. Following the introduction of adjunctive dexamethasone treatment the mortality rate of pneumococcal meningitis has decreased from 30 to 20 % \[[@CR8]--[@CR10]\], but new treatments are urgently needed \[[@CR11]--[@CR13]\]. Interindividual differences in severity of disease and outcome may be determined by host genetic variation \[[@CR14], [@CR15]\]. So far, genetic association studies in pneumococcal meningitis have used a candidate gene approach in which variations in genes of interest were studied \[[@CR15]--[@CR17]\], focusing on genes in the immune system, for example the toll-like receptor signalling cascade and the complement system \[[@CR14], [@CR15]\].

Whole-genome association studies, using an unbiased approach, may identify new candidate genes and pathophysiological mechanisms leading to an unfavourable outcome in pneumococcal meningitis \[[@CR17]\]. Such studies should be performed prospectively, using a clear definition of cases with microbiological confirmation, and validated outcome scales \[[@CR18]\]. In 2006, we started a nationwide prospective cohort study to identify and characterize host genetic traits and bacterial genetic factors controlling occurrence and outcome of bacterial meningitis (MeninGene) \[[@CR9], [@CR18]\]. Here, we report our genome wide association study on the host side, analysing the associations between human genome variants and functional outcome in patients with pneumococcal meningitis using the Human Exome BeadChip. We subsequently validated the role of one of the top hits, *AKT3*, in a pneumococcal meningitis mouse model. Finally, we studied whether patients with the associated *AKT3* rs10157763 risk allele had specific clinical characteristics or cerebrospinal fluid (CSF) inflammatory marker profiles.

Materials and methods {#Sec2}
=====================

Dutch bacterial meningitis cohort {#Sec3}
---------------------------------

In a nationwide prospective cohort study (MeninGene) we included patients with community-acquired bacterial meningitis with an age of 16 years or older with positive CSF cultures who were identified by The Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) from March 2006 to October 2011 \[[@CR14]\]. The NRLBM receives bacterial isolates from approximately 85 % of bacterial meningitis patients in the Netherlands and provided the names of the hospitals where patients with bacterial meningitis had been admitted in the previous 2--6 days. Physicians of the hospitals were contacted after which the treating physician obtained informed consent from the patient or their legal representative. Online case record forms were collected through a secured website and included data on symptoms during the hospitalized period, treatment, complications and outcome. Patients with hospital-acquired bacterial meningitis and negative CSF cultures were excluded. Outcome was graded at discharge according to the Glasgow Outcome Scale (GOS), a well validated instrument with good inter-observer agreement \[[@CR19]\]. On this five-point scale a score of 1 indicates death, 2 a vegetative state, 3 severe disability, 4 moderate disability, and a score of 5 mild or no disability.

Blood for DNA extraction was collected in sodium/EDTA tubes and DNA-isolation was performed with the Gentra Puregene isolation kit (Qiagen) according to manufacturer's protocol thereafter the yield and quality of the extractions were determined to ensure appropriate conditions for genotyping.

Genotyping and quality control {#Sec4}
------------------------------

Patients were genotyped on the Illumina HumanExome BeadChip v1.1 consisting of \>24,0000 markers, with approximately 75 % of these markers having a minor allele frequency (MAF) \< 0.05. The genotyping was carried out in collaboration with the Human Genome Facility and the department of Epidemiology, Erasmus MC, the Netherlands as part of the Netherlands ExomeChip Project. After genotyping we performed genotype-calling on all our MeninGene samples (*N* = 1322) to improve calling accuracy and all non-pneumococcal meningitis patients were removed after quality control (QC). All autosomal SNPs were called using GenomeStudio software, from Illumina, with the GenTrain2.0 cluster algorithm using the protocol as described before \[[@CR20]\].

Called data was exported in PLINK format for final sample and SNP QC \[[@CR21]\]. All samples with \> 5 % missing genotypes were removed. High quality, independent SNPs with less than 1 % missing-genotypes, non-significant differences between cases and controls with respect to rate of missing genotypes, MAF \>5 % and Hardy-Weinberg equilibrium (HWE) *p*-value \> 1 × 10^−3^ were used to determine relatedness between patients, heterozygosity and ancestry. Individuals with second degree, or higher degree relatedness, heterozygosity above or below three standard deviations and non-European decent were left out. Finally QC was performed by removing all SNPs with \>5 % missing genotypes and HWE *p*-value \< 1 × 10^−6^.

Mice {#Sec5}
----

8- to 12-week-old male C57BL/6 N mice were obtained from Charles River, whereas *Akt3*^-/-^ mice (backcrossed at least 10 times to a C57BL/6 N background), generated as described elsewhere \[[@CR22]\] were bred and maintained at the animal facility at the Academic Medical Center of Amsterdam. The mice were kept to a controlled 12 h light/dark cycle and food and water were provided *ad libitum.*

Experimental pneumococcal meningitis model {#Sec6}
------------------------------------------

Pneumococcal meningitis was induced by intracisternal inoculation with *S. pneumoniae* (serotype 3, American Type Culture Collection \#6303) as described previously \[[@CR18], [@CR23]--[@CR25]\]. In brief, wild-type and *Akt3*^-/-^ mice (*n* = 12 per group) were randomly and blind inoculated with 1 μl bacterial suspension containing 1 × 10^4^ CFU *S. pneumoniae* into the cisterna magna under Isofluran (Baxter) anaesthesia. Six mice per group inoculated with sterile saline (Baxter) were used as controls*.* Cultures were adjusted such that each final 1 μl inoculum contained 1 × 10^4^ CFU. Immediately after intracisternal inoculation, mice were assessed for neurologic damage as a result of the puncture. No mice suffered from neurological damage as a result of puncture and had to be excluded. Mice were observed during 48 h post infection and clinical signs of meningitis were blindly scored every four hours as previously described \[[@CR23]\]. In brief, the maximum score was determined by the estimated contribution of the variable to overall health of the mouse: weight loss (0--4 points), activity (0--4 points), time to return to upright position (0--6 points), state of skin/fur (0--3 points), posture (0--2 points), eye discharge or protrusion (0--4 points), respiration rate (0--4 points), irregular/labored breathing (0--4 points), epilepsy, limb paresis or ataxia (0--10 points). Animals reaching endpoint criteria were humanely killed. In another set of experiments, at 6, 24 and 30 h post infection, 12 mice/group were anesthetized by intraperitoneal injection of 190 mg/kg ketamine (Eurovet Animal Health) and 0.3 mg/kg dexmedetomidine (Pfizer Animal Health) followed by cardiac puncture for blood collection and perfusion of organs with sterile isotonic saline via the left ventricle. CSF was collected by puncture of the cisterna magna. Brain, lung and spleen were harvested, placed on ice, processed and stored as described before \[[@CR23]\]. EDTA blood was centrifuged at 2000 × g for 15 min. Plasma was stored at −80 °C for further analysis.

Real-time PCR {#Sec7}
-------------

Total RNA was extracted from murine brain homogenates using TriPure reagent (Sigma-Aldrich). The purity of the RNA was assessed by the ratio of absorbance at 260 and 280 nm. RNA purity was within a range of 2.0--2.1. RNA was stored in aliquots at −80 °C until used for reverse transcription. For complementary DNA (cDNA) synthesis, RNA was treated with RQ1 RNase-free DNase (Promega) and reverse transcribed with SuperScript II Reverse Transcriptase and random hexamers (Life Technologies). The real-time polymerase chain reaction (RT-PCR) measurement of individual cDNAs was performed on a Bio-Rad MyiQ Single-Color RT-PCR Detection System using the Bio-Rad iQ SYBR Green Supermix (Bio-Rad Laboratories). The Non-POU-domain containing octamer binding protein (*nono*, housekeeping gene) primers were described previously \[[@CR26]\]. *Akt3* cDNA was amplified with a forward 5′-CATCTGAAACAGACACCCGATA-3′ and a reverse 5′-GTCCGCTTGCAGAGTAGGAG-3′ primer for mouse *akt3. Dctn4* cDNA was amplified with a forward 5′- CACCCATGTGACTGTGTTGG and a reverse 5′-TGAAGATGCCCACTTTGTTG primer for a mouse *dctn4. Raet1E* was amplified with a forward 5′-GGATACACCAACGGGCTG and a reverse 5′-GTCACACCCAGGGAAGGTC primer for a mouse *raet1e* (all Applied Biosystems). A negative control without the Reverse Transcriptase was also used. The expression data were normalized to the *nono* reference gene. Data were analyzed using the Bio-Rad MyiQ Optical system Software version 1.0.

Murine histopathology and immunohistochemistry {#Sec8}
----------------------------------------------

Histopathology was performed on the right cerebral hemisphere fixed in 4 % paraformaldehyde and paraffin embedded. Coronal 5 μm sections of the right hemisphere were cut for subsequent staining with hematoxylin and eosin (HE) according to standard procedures. HE staining were performed to visualize meningeal infiltration, parenchymal damage, vascular inflammation, thrombosis and ventriculitis on a three point scale (Additional file [1](#MOESM1){ref-type="media"}). Sections of mice 24 h after induction of pneumococcal meningitis (*n* = 12 per group) were scored. Tissue sections were stained for Caspase-3 using immunohistochemical procedures in order to assess hippocampal apoptosis, as described previously \[[@CR24]\].

Determination of cytokines and chemokines {#Sec9}
-----------------------------------------

The murine cytokines interleukin (IL)-1β, IL-6, IL-10 and tumour-necrosis factor-α (TNF-α) and the chemokines keratinocyte chemoattractant (KC) and macrophage inflammatory protein (MIP)-2 were determined in plasma and brain homogenates by Luminex technology using a mouse Bioplex kit (Bio-Rad Laboratories) as described before \[[@CR25]\]. The human cytokines IL-1β, IL-6, IL-10 and TNF-α were determined in CSF collected from the diagnostic lumbar puncture. CSF samples were centrifuged and supernatant was aliquoted and stored at −80 °C until analysis. All analytes were measured with Luminex**®** xMAP**®** technology using Milliplex**®** map multiplex assay's (Millipore Billerica). CSF was diluted 1:50 in assay buffer provided with the Multiplex assay and inflammatory mediators were measured according to the manufacturer's instructions. CSF was available in 271 of the 689 (39 %) of pneumococcal meningitis patients.

Statistics {#Sec10}
----------

All patients with pneumococcal meningitis were included in the genetic association analysis for meningitis disease severity/outcome. Severity/outcome was determined by grouping patients on their GOS score where score 1 until 4 together was labelled unfavourable and score 5 as favourable outcome. All calculations have been conducted using PLINK 1.9 \[[@CR27]\]. Differences between favourable and unfavourable outcome were calculated using the Fisher's exact test on allelic association. For the genetic association study, based on 321 patients with a favourable outcome and 152 with unfavourable outcome, for 240,000 variants and a MAF of 0.25, we had 80 % power to detect variants with a OR of 3.4 or higher after Bonferroni correction. Cytokine level differences between genotypes were compared using a Mann-Whitney *U* test.

We used a multivariable logistic regression analysis to calculate OR and 95 % CI to assess the strength of the association among potential risk factors (including identified polymorphisms) and outcome. Murine gene expression, bacterial load and inflammatory response data were compared using Mann-Whitney U tests. Survival curves were compared using a log rank test and clinical scores were compared using a linear mixed model assuming an exponential and group specific time effect. For all analyses, SPSS (version 22) was used; differences were considered statistically significant at *P* \< 0.05.

Results {#Sec11}
=======

Nationwide prospective cohort study {#Sec12}
-----------------------------------

In a prospective nationwide study we included 1005 episodes of culture-proven community-acquired bacterial meningitis in 993 patients. The distribution of causative bacteria was *S. pneumoniae* in 720 (72 %), *Neisseria meningitidis* in 105 (11 %), and other bacteria in 180 (18 %) episodes. DNA samples were obtained from 472 pneumococcal meningitis patients (66 %) of whom 430 were from Caucasian population (91 %). The mean age of pneumococcal meningitis patients for whom DNA was available was 58 years and 221 (47 %) were male (Table [1](#Tab1){ref-type="table"}). Predisposing conditions, most commonly otitis or sinusitis (218 episodes, 46 %) or an immunocompromised state (124 episodes, 26 %) were present in 322 episodes (68 %). Upon presentation epileptic seizures occurred in 33 patients (7 %). During clinical course, new focal neurologic deficits developed in 24 % of patients. Outcome was prospectively evaluated using a validated outcome scale \[[@CR19]\], the GOS, a score of 1 to 4 was defined as unfavourable outcome, a score 5 as favourable outcome), in all 472 patients with pneumococcal meningitis with DNA available: 151 (32 %) patients had an unfavourable outcome and 37 (8 %) died.Table 1Clinical characteristics of 472 patients with community-acquired pneumococcal meningitis^a^CharacteristicCharacteristicAge -- yr58 ± 15Indexes of CSF inflammation^c^Male sex -- no (%)221 (47 %) Opening pressure (mm H~2~O)42 ± 11Duration of symptoms \<24 h225/461 (49 %) White blood cell count (/mm^3^)2417 ± 5648Pretreatment with antibiotics58/459 (13 %)  \<1.000/mm^3^130/454 (29 %)Predisposing conditions322/472 (68 %) Protein -- g/L4.7 ± 3.2Otitis or sinusitis218/471 (46 %) CSF: blood glucose ratio0.13 ± 0.18Immunocompromised124/472 (26 %)Positive blood cultures337/420 (80 %)Symptoms and signs on presentation^b^ComplicationsHeadache363/427 (85 %) Cardiorespiratory failure170/466 (36 %)Neck stiffness356/454 (78 %) Focal neurologic deficits109/455 (24 %)Epileptic seizures33/454 (7 %) Epileptic seizures69/460 (15 %)Systolic blood pressure -- mmHg149 ± 29Score on Glasgow Outcome ScaleHeart rate -- beats/min100 ± 21 1 -- death37 (8 %)Body temperature -- °C38.8 ± 1.3 2 -- vegetative state1 (0.2 %)Score on Glasgow Coma Scale^c^11 ± 3 3 -- severe disability23 (5 %)\<8 indicating coma63/472/87 %) 4 -- moderate disability90 (19 %)Focal neurologic deficits109/455 (25 %) 5 -- good recovery321 (68 %)^a^ Data are number/number evaluated (percentage), continuous data are mean ± SD. ^b^Systolic blood pressure was evaluated in 469 patients, heart rate in 466, temperature in 471. ^c^CSF opening pressure was evaluated in 165 patients, CSF WBC count in 454 patients, CSF protein in 452, CSF blood: glucose ratio in 452

Genetic association study {#Sec13}
-------------------------

A total of 472 patients with pneumococcal meningitis were genotyped on the Illumina Human Exome BeadChip. Of the top five candidate single nucleotide polymorphisms (SNPs) associated with unfavourable outcome (Table [2](#Tab2){ref-type="table"}) two pairs of candidate SNPs were in linkage disequilibrium (LD), the rs11954652 and rs6869603 within the *DCTN4* gene (odds ratio \[OR\] 5.6 for unfavourable outcome, 95 % confidence interval \[CI\] 2.4--12.9, *p* = 2.4× 10^−5^). Rs11954652 is a missense variant and rs6869603 is a variant within a regulatory element before the *DCTN4* gene. SNPs rs3798763 and rs6925151 are also in LD and lay within the *RAET1E* gene (OR 1.9 for unfavourable outcome, 95 % CI 1.4--2.6, *p* =9.4× 10^−5^). Rs3798763 is an intron variant and rs6925151 is missense variant. Rs10157763 is located within the intron of the *AKT3* gene (OR 1.88 for unfavourable outcome, 95 % CI 1.4--2.6, *p* = 9.9× 10^−5^). The missense variations within *DCTN4* and *RAET1E* had no predicted impact of amino acid substitution on structure or function of the gene using PolyPhen-2 \[[@CR28]\]. The potential effect of other three variations on the protein structure or function was unclear.Table 2Novel SNPs associated with unfavorable outcome in patients with pneumococcal meningitisGeneChrVariation typedbSNIPIDBPAllelesAllele frequency*P*BONF_POR (+/− 95 CI)Effect^d^Other^e^UFF*DCTN4* ^*a*^5Upstream gene variantrs6869603^b^150142849GA0.070.012.4 × 10^−05^15.6 (2.4--12.9)*DCTN4*5F349L, F342L, F285Lrs11954652^b^150097883GC0.070.012.4 × 10^−05^15.6 (2.4--12.9)*RAET1E*6E89E, E53Ers3798763^c^150211100GA0.370.239.4 × 10^−05^11.9 (1.4--2.6)*RAET1E*6R128H, R92Hrs6925151^c^150210723GA0.370.239.4 × 10^−05^11.9 (1.4--2.6)*AKT3*1Silentrs10157763243995041AG0.400.269.9 × 10^−05^11.9 (1.4--2.6)BP denotes base pair, UF unfavourable outcome, F favourable outcome^a^ Variation within a regulatory area of this gene^b^,^c^ Markers in linkage disequilibrium (LD)^d^ Risk allele associated with unfavorable outcome^e^ Allele without risk

Role of *akt3* in the pneumococcal meningitis mouse model {#Sec14}
---------------------------------------------------------

To explore the role of *AKT3, DCTN4*, and *RAET1E* during pneumococcal meningitis we determined their brain expression levels in our mouse model \[[@CR23]\]. Mice infected intracisternally with 10^4^ CFUs *S. pneumoniae* ATCC 6303, had low *akt3* mRNA expression in uninfected brain, which decreased 30 h post-infection; *dctn4* brain transcript levels of mice showed no increase after infection (Fig. [1a](#Fig1){ref-type="fig"}). No *raet1e* product was detected. Subsequently, we evaluated the functional role of *Akt3* in pneumococcal meningitis in our mouse model using knock-out mice. In a randomized investigator-blinded study, *Akt3*^*-/-*^ mice died faster than wild-type mice when incisternally infected with 10^4^ CFUs of *S. pneumoniae* ATCC 6303 (*p* = 0.036; Fig. [1b](#Fig1){ref-type="fig"}). Disease severity scores were also higher in *Akt3*^*-/-*^ mice than wild-type mice (p = 0.002; Fig. [1c](#Fig1){ref-type="fig"}). The higher mortality was not caused by differences in bacterial loads or inflammatory response in *Akt3*^*-/-*^ mice as compared with wild-type mice. At 24 h post infection, we observed no difference in bacterial loads in CSF, brain, blood, lung, spleen and testis (Fig. [1d](#Fig1){ref-type="fig"}). Levels of TNF-α in brain homogenate levels were higher in *Akt3*^*-/-*^ mice (*p* = 0.006), but IL-1β, IL-6, IL-10, KC and MIP-2 levels were similar between *Akt3*^*-/-*^ and wild-type mice (Fig. [1e](#Fig1){ref-type="fig"}). Histopathological examination showed higher histopathology scores for parenchymal damage (infiltration) and vascular infiltration (large meningeal artery inflammation) in *Akt3*^*-/-*^ mice as compared to wild-type mice; there were no differences in parenchymal damage (infarction, haemorrhage, abscess), vascular infiltration (small parenchymal vessel inflammation) meningeal inflammation, ventriculitis, thrombosis, or hippocampal apoptosis between *Akt3*^*-/-*^ and wild-type mice (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}).Fig. 1*dctn4* and *akt3* mRNA expression levels and role of *Akt3* in experimental pneumococcal meningitis. **a** Wild-type mice were infected with 1 × 10^4^ colony-forming units (CFU) of *S. pneumoniae* serotype 3, strain 6303 via intracisternal inoculation. mRNA levels were assessed after 6 and 30 h in brain tissue (*n* = 6 control mice and 12 infected mice). **b** Kaplan-Meier survival of mice following intracisternal injection with 1 × 10^4^ CFU of *S. pneumoniae* serotype 3, strain 6303. Survival was monitored two to four times a day over a 48 h period and data analysed using Log-rank test. **c** Clinical scores for each infected mouse group used in the survival study. Scores were compared using a nonlinear mixed effects model, assuming exponential growth (y = β~0~ + e^(β1x)^). **d** Bacterial counts in organs and plasma during *S. pneumoniae* meningitis. **e** Selected cytokine/chemokine levels in brain homogenates of infected mice. Each circle represents a single mouse and the bar indicates the group median expression. Significance was determined using the non-parametric test Mann-Whitney UFig. 2Histopathology scores in *S. pneumoniae*-infected mouse brains. Histopathological changes in mice 24 h after intracisternal injection with 1 × 10^4^ CFU of *S. pneumoniae* serotype 3, strain 6303. Data are represented as median. Statistical analysis was performed using Mann-Whitney *U* test. **a** Parenchymal damage, **b** vascular infiltration, **c** meningeal infiltration, **d** ventriculitis, **e** thrombosis, **f** caspase-3 positive cellsFig. 3Histopathology during experimental *S. pneumoniae* meningitis. **a**-**e** Representative haematoxylin and eosin and **f** caspase-3- stained sections of a wild-type brain infected with 1 × 10^4^ colony-forming units (CFU) of *S. pneumoniae* serotype 3, strain 6303 via intracisternal inoculation (24 h post inoculation). **a** Red asterisks show parenchymal infiltration of neutrophils. Arrows indicate **b** inflammation of and destruction of meningeal vessel, **c** parenchymal bleeding, **d** thrombosis in meningeal vessel, **e** apoptotic cell with pyknotic nucleus in the dentate gyrus of hippocampus and **f** caspase-3 positive cells in the dentate gyrus of hippocampus

*AKT3* rs10157763 variant and risk factors for unfavourable outcome {#Sec15}
-------------------------------------------------------------------

Having validated the role of *Akt3* in pneumococcal meningitis, we explored the associations between this polymorphism (rs10157763) and clinical features (Table [3](#Tab3){ref-type="table"}). Consistent with our animal data, we found no differences in CSF protein cytokine levels of IL-1β, IL-6 and IL-10 between patients with risk or non-risk alleles at the diagnostic lumbar puncture (Fig. [4](#Fig4){ref-type="fig"}). In contrast to the mouse experiments, no differences in CSF TNF-α concentration was observed between genotypes. Patients with the risk genotype (AA: 9.9 %) had an increased risk for seizures (OR 2.94, 95 % CI 1.11--7.80), less frequently exhibited fever (OR 0.43, 95 % CI 0.21--0.84), and had lower scores on the GCS score on admission (median 9 vs 11, *p* = 0.006) as compared with the non-risk genotypes (GG and AG: 40.6 and 49.5 % respectively). In a multivariable regression analysis, including previously identified risk factors for unfavourable outcome (age, CSF white blood cell count \< 1000/mm^3^, score on the GC, blood thrombocyte count, immunocompromise, otitis media, and/or sinusitis) \[[@CR2], [@CR9], [@CR29]\], the predictive effect of rs10157763 remained robust (OR 3.6, 95 % CI 1.66--7.87; *p* = 0.001).Table 3Clinical characteristics and outcome per genotype in 396 white patients with community-acquired pneumococcal meningitis^a^CharacteristicGG (*n* = 195)AG (*n* = 162)AA (*n* = 39)*p*-value recessive modelAge58 ± 1460 ± 1356 ± 17Gender86 (44 %)79 (49 %)17 (44 %)0.63Glasgow Coma Scale Score11 ± 311 ± 39 ± 30.006Seizures on admission12/188 (7 %)10/158 (6 %)6/36 (17 %)0.024Fever168 (86 %)123 (76 %)26 (67 %)0.019Focal neurologic abnormalities43 (22 %)58 (36 %)14 (36 %)0.28Leukocytes \<100050 (26 %)52 (32 %)13 (36 %)0.36Respiratory failure39/191 (21 %)44/157 (29 %)13 (33 %)0.29Mechanical ventilation56/186 (30 %)64/158 (41 %)18/38 (47 %)0.19Seizures during admission25/192 (14 %)27/154 (18 %)5/39 (13 %)0.76Focal neurologic deficit during admission44/188 (23 %)38/155 (24 %)15/37 (41 %)0.02Unfavourable outcome57/195 (29 %)52/162 (32 %)22/38 (58 %)0.001Death12/195 (6 %)13/162 (8 %)4/38 (11 %)0.43Fig. 4CSF protein cytokine levels between patients with risk or non-risk alleles. **a**-**d** The cytokines IL-6, TNF-α, IL-1β and IL-10 were determined in pneumococcal meningitis patient CSF samples collected from the diagnostic lumbar puncture. Data are represented as median of individual patients grouped on their AKT3 rs10157763 genotypes AA, AG and GG. Statistical analysis was performed using Mann-Whitney *U* test

Discussion {#Sec16}
==========

In the first genome wide association study on outcome in pneumococcal meningitis gene variants in *AKT3, DCTN4* and *RAET1E* were associated with unfavourable outcome in adults with pneumococcal meningitis. As no clinical cohort is available for validation \[[@CR18]\], we explored our findings in our pneumococcal meningitis mouse model. The identified downregulation and increased mortality during experimental meningitis confirmed a role of Akt3 during pneumococcal meningitis, although the exact mechanism remains unclear.

In pneumococcal meningitis, brain damage and unfavourable outcome result from massive neutrophil recruitment and inflammation of the brain, reflected by CSF pleocytosis, seizures, and cerebrovascular complications \[[@CR30], [@CR31]\]. Patients with the *AKT3* risk allele had a higher level of disease severity, consisting of lower level of consciousness, and a higher risk for epileptic seizures. AKT3 is a critical signalling protein in the Phosphoinositide 3-kinase pathway involved in diverse cellular process such as cell survival, growth, proliferation, metabolism and migration \[[@CR32]\]. Inhibition of AKT has been shown to promote apoptosis in many cell types \[[@CR33], [@CR34]\].

AKT has been shown to be essential to induce neutrophil extracellular traps, which are pro-inflammatory and important to kill bacteria \[[@CR35]\]. In a model of myelin-oligodendrocyte glycoprotein--induced experimental autoimmune encephalomyelitis (EAE), *Akt3*^-/-^ mice were more severely affected than wild-type mice \[[@CR36]\]. Experiments using bone marrow chimeras demonstrated that *Akt3*^-/-^ mice receiving *Akt3*-deficient bone marrow cells had elevated clinical scores relative to control wild-type mice reconstituted with wild-type cells, indicating that altered function of both central nervous system (CNS) cells and bone marrow-derived immune cells contributed to the phenotype \[[@CR36]\]. These experiments showed that *Akt3*^-/-^ mice have increased inflammatory cytokine expression in spinal cord during acute EAE \[[@CR36]\]. In our experiments, *Akt3*^-/-^ mice had similar bacterial outgrowth and mild host inflammatory response as compared to wild-type mice. For neuropathology, we only evaluated a relatively early time-point (24 h) without antibiotic treatment in which gross pathology usually do not present yet. As knockout mice started to die after 24 h however, we were unable to postpone this time point without introducing selection bias in our results. Nevertheless, *Akt3*^-/-^ mice showed increased parenchymal infiltration and artery inflammation as compared to wild-type mice, suggesting an important role of AKT3 in brain integrity and inflammation. In line, a plausible mechanism in which AKT3 is involved in meningitis is by influencing the inflammatory response through influencing apoptosis of inflammatory cells.

An alternative explanation for the poor prognosis associated with AKT3 could be a decreased seizure threshold. Enhanced activation of the mammalian target of rapamycin (mTOR)-signalling cascade has been identified in focal malformations of cortical development subtypes, which have been collectively referred to as "mTORopathies." Mutations in mTOR regulatory genes such as AKT3 have been associated with epilepsy \[[@CR37], [@CR38]\]. Upstream and downstream molecules involved in serine/threonine kinase AKT pathways, including *Akt3,* were found to be involved in epilepsy pathophysiology \[[@CR32]\]. Indeed, patients with the risk genotype presented with a high rate of epileptic seizures, but we did not observe a higher seizure rate in our animal model. The animals however, were checked every 4 h (24 h after inoculation) and we did not perform a continuous (video) surveillance for seizures. We previously described that community acquired bacterial meningitis is complicated by seizures in 17 % of episodes and seizures are associated with a high mortality rate (41 %) \[[@CR6]\]. Seizures have been associated with severe CNS inflammation and structural CNS lesions, but it is unclear whether the seizures are due to, or cause CNS damage \[[@CR6]\].

The genetic variant rs10157763 in AKT3 has been previously associated with aggressive prostate carcinoma and renal cell carcinoma \[[@CR39]\]. rs10157763 variant has been described to alter the transcriptional factor binding sites (TFBS) for transcription factors that regulate AKT3 expression.

Genetic variants in *DCTN4* and *RAET1E* were also associated with functional outcome in pneumococcal meningitis, but these findings will need to be validated. DCTN4 is a component of the dynein-dependent motor that moves autophagosomes along microtubules into lysosomes for degradation as part of the autophagy process - a highly conserved cellular quality control mechanism to transport and degrade damaged proteins and microbes \[[@CR40], [@CR41]\]. Exome sequencing of extreme phenotypes previously has identified DCTN4 as a modifier of chronic *Pseudomonas aeruginosa* infection in patients with cystic fibrosis \[[@CR42]\]. RAET1E is a major histocompatibility complex class 1-like molecule and is a functional ligand for an activating receptor expressed on the surface of immune antigen-presenting cells such as natural killer (NK) cells, CD8(+) T cells, and subsets of CD4(+) T cells \[[@CR43]\]. High levels of RAET1E expression on antigen-presenting cells induces down-regulation of NK cell activation by a regulatory T-cell subset \[[@CR44]\]. NK cells have been shown to be important for the protection against various microbial pathogens, including *S. pneumoniae* \[[@CR45]\], and have shown to contribute to mortality in experimental pneumococcal pneumonia \[[@CR46]\]. We did not further study these genes in our animal model as we did not find the genes differentially expressed during meningitis, although this does not completely negate a role in the pathophysiology of pneumococcal meningitis.

Our study has several limitations. First, captured variations with the Human Exome BeadChip are mainly restricted to protein coding regions and used as stand-alone array for identification of the causal variant can be difficult.

Second, some selection bias was possibly introduced since DNA was not available for a considerable proportion of patients (34 %), particularly those with more severe disease. Inclusion of patients with less severe disease will decrease study power to detect genetic variants associated with outcome, resulting in more type II errors (accepting the null hypothesis when it is false). The nationwide design allowed us to detect this selection bias. Third, we could not validate our findings of the genetic association study in a different cohort. The candidate SNPs were associated with unfavourable outcome with a *p*-value lower than 1 × 10^−4^, indicating that findings could still be a type I error. However, no cohorts are currently available for outcome in adult pneumococcal meningitis to validate our results. Therefore, we validated one genetic variant that was upregulated during meningitis in our adult mouse pneumococcal meningitis model \[[@CR23]\]. Fourth, to further contribute to elucidate the underlying mechanism(s) on meningitis-associated brain pathology, information regarding tissue protein expression of Akt3 and TNF-α, phenotypical characterization of the cell infiltrate and experiments using TNF- α blocking agents should be assessed in further experiments.

Conclusions {#Sec17}
===========

In conclusion, we identified gene variants in *AKT3, DCTN4* and *RAET1E* to be associated with unfavourable outcome in adults with pneumococcal meningitis. We validated the role of Akt3 in our experimental pneumococcal meningitis model. Our study show that a GWAS approach in pneumococcal meningitis provides new insights in the pathophysiology of pneumococcal disease and may provide new leads for the development of adjunctive therapies.
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